Search results for "ANTIFUNGAL RESISTANCE"

showing 5 items of 5 documents

Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris

2018

Abstract Candida spp. infections are a major cause of morbidity and mortality in critically ill patients. Candida auris is an emerging multi-drug-resistant fungus that is rapidly spreading worldwide. Since the first reports in 2009, many isolates across five continents have been identified as agents of hospital-associated infections. Independent and simultaneous outbreaks of C. auris are becoming a major concern for healthcare and scientific community. Moreover, laboratory misidentification and multi-drug-resistant profiles, rarely observed for other non-albicans Candida species, result in difficult eradication and frequent therapeutic failures of C. auris infections. The aim of this review…

0301 basic medicineSettore MED/07 - Microbiologia E Microbiologia Clinicamedicine.medical_specialty030106 microbiologySettore MED/41 - AnestesiologiaVirulenceAntimicrobial resistanceCritical Care and Intensive Care MedicineMicrobiology03 medical and health sciencesInvasive fungal infectionAntibiotic resistanceEpidemiologymedicineCandidaResistance (ecology)business.industryCritically illlcsh:Medical emergencies. Critical care. Intensive care. First aidCandidemiaOutbreakAntifungal resistancelcsh:RC86-88.9Candida aurisCandida sppC. aurisC. auris Candida Candidemia Invasive fungal infection Antimicrobial resistance Antifungal resistancebusinessJournal of Intensive Care
researchProduct

Fungal Biofilms as a Valuable Target for the Discovery of Natural Products That Cope with the Resistance of Medically Important Fungi—Latest Findings

2021

The development of new antifungal agents that target biofilms is an urgent need. Natural products, mainly from the plant kingdom, represent an invaluable source of these entities. The present review provides an update (2017–May 2021) on the available information on essential oils, propolis, extracts from plants, algae, lichens and microorganisms, compounds from different natural sources and nanosystems containing natural products with the capacity to in vitro or in vivo modulate fungal biofilms. The search yielded 42 articles; seven involved essential oils, two Brazilian propolis, six plant extracts and one of each, extracts from lichens and algae/cyanobacteria. Twenty articles deal with th…

Microbiology (medical)FusariumCyanobacteriaFUNGAL BIOFILMnatural productsMicroorganism<i>Candida</i> spp.CryptococcusCANDIDA SPPRM1-950ReviewBiochemistryMicrobiologyCRYPTOCOCCUS SPPFUSARIUM SPPmechanisms of antibiofilm actionNATURAL PRODUCTSAspergillus fumigatusMicrobiology//purl.org/becyt/ford/1 [https]//purl.org/becyt/ford/1.4 [https]Pharmacology (medical)General Pharmacology Toxicology and PharmaceuticsLichenFusarium spp.ANTIFUNGAL RESISTANCECandida spp.MECHANISMS OF ANTIBIOFILM ACTIONbiology<i>Cryptococcus</i> spp.filamentous fungiBiofilmCryptococcus spp.PropolisFILAMENTOUS FUNGIantifungal resistancebiology.organism_classificationInfectious Diseases<i>Fusarium</i> spp.fungal biofilmTherapeutics. PharmacologyAntibiotics
researchProduct

Role of the Non-Canonical RNAi Pathway in the Antifungal Resistance and Virulence of Mucorales

2021

Mucorales are the causal agents for the lethal disease known as mucormycosis. Mortality rates of mucormycosis can reach up to 90%, due to the mucoralean antifungal drug resistance and the lack of effective therapies. A concerning urgency among the medical and scientific community claims to find targets for the development of new treatments. Here, we reviewed different studies describing the role and machinery of a novel non-canonical RNAi pathway (NCRIP) only conserved in Mucorales. Its non-canonical features are the independence of Dicer and Argonaute proteins. Conversely, NCRIP relies on RNA-dependent RNA Polymerases (RdRP) and an atypical ribonuclease III (RNase III). NCRIP regulates the…

AntifungalTransposable element0301 basic medicineMucoralesAntifungal Agentstransposonmedicine.drug_classRNA Stability030106 microbiologyAntifungal drugVirulenceReviewQH426-470mucormycosis03 medical and health sciencesDrug Resistance FungalRNA interferenceFongsmedicineGeneticsbiochemistryRNA MessengerRibonuclease IIIepimutantGenetics (clinical)Genome stabilityGeneticsRdRPR3B2biologyMucormycosisnon-canonical RNAiRNA FungalArgonauteantifungal resistancemedicine.diseasebiology.organism_classificationvirulenceRNA silencing030104 developmental biologyNon canonicalbiology.proteinInfeccióMucoralesRNA Interferencegenome stabilitySignal TransductionDicerGenes
researchProduct

Candida auris: An Overview of How to Screen, Detect, Test and Control This Emerging Pathogen

2020

The multidrug-resistant yeast Candida auris is associated with invasive infections in critically ill patients and has been isolated in different countries worldwide. Ease of spread, prolonged persistence in the environment and antifungal drug resistance pose a significant concern for the prevention of transmission and management of patients with C. auris infections. Early and correct identification of patients colonized with C. auris is critical in containing its spread. However, this may be complicated by C. auris strains being misidentified as other phylogenetically related pathogens. In this review, we offer a brief overview highlighting some of the critical aspects of sample collection,…

0301 basic medicineMicrobiology (medical)<i>Candida auris</i><i>Candida auris</i> identification030106 microbiologyAntifungal drugReviewBiochemistryMicrobiologyMicrobiology03 medical and health sciencesEmerging pathogenMedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsTransmission (medicine)business.industryCritically illscreeningantifungal resistance testinglcsh:RM1-950Candida aurisCandida auris identificationlcsh:Therapeutics. Pharmacology030104 developmental biologyInfectious DiseasesCandida aurisSample collectionbusinessAntibiotics
researchProduct

Epidemiology, clinical characteristics, resistance, and treatment of infections by

2018

Candida spp. infections are a major cause of morbidity and mortality in critically ill patients. Candida auris is an emerging multi-drug-resistant fungus that is rapidly spreading worldwide. Since the first reports in 2009, many isolates across five continents have been identified as agents of hospital-associated infections. Independent and simultaneous outbreaks of C. auris are becoming a major concern for healthcare and scientific community. Moreover, laboratory misidentification and multi-drug-resistant profiles, rarely observed for other non-albicans Candida species, result in difficult eradication and frequent therapeutic failures of C. auris infections. The aim of this review was to p…

Invasive fungal infectionCandidemiaReviewAntifungal resistanceC. aurisAntimicrobial resistanceCandidaJournal of intensive care
researchProduct